Jean-Marie Leclerc
Overview
Explore the profile of Jean-Marie Leclerc including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
490
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mootoosamy C, Kondyli M, Serfaty S, Tremblay D, Gagne V, Ribere M, et al.
Pharmacogenomics
. 2023 Mar;
24(4):199-206.
PMID: 36946317
We previously conducted exome-wide association study in acute lymphoblastic leukemia patients and identified association of five SNPs with asparaginase-related thrombosis. Here we aimed to replicate these findings in an independent...
2.
Athale U, Flamand Y, Blonquist T, Stevenson K, Spira M, Asselin B, et al.
Pediatr Blood Cancer
. 2022 Mar;
69(8):e29581.
PMID: 35316569
Background/objectives: Although thromboembolism (TE) is a serious complication in patients with acute lymphoblastic leukemia (ALL), thromboprophylaxis is not commonly used due to the inherent bleeding risk in this population. Identifying...
3.
Tran T, Langlois S, Meloche C, Caron M, Saint-Onge P, Rouette A, et al.
Blood Adv
. 2021 Dec;
6(4):1329-1341.
PMID: 34933343
The molecular hallmark of childhood acute lymphoblastic leukemia (ALL) is characterized by recurrent, prognostic genetic alterations, many of which are cryptic by conventional cytogenetics. RNA sequencing (RNA-seq) is a powerful...
4.
Vrooman L, Blonquist T, Stevenson K, Supko J, Hunt S, Cronholm S, et al.
J Clin Oncol
. 2021 Jul;
39(31):3496-3505.
PMID: 34228505
Purpose: Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia (ALL) Consortium Protocol 11-001 assessed efficacy and toxicity of calaspargase pegol (calaspargase), a novel pegylated asparaginase formulation with longer half-life, compared with the...
5.
Kondyli M, Tremblay D, Rezgui A, Serfaty S, Gagne V, Ribere M, et al.
Leuk Res
. 2021 Jul;
109:106650.
PMID: 34198115
No abstract available.
6.
Dorval S, Gantt S, Leclerc J, Laverdiere C, Ovetchkine P, Tapiero B
Pediatr Blood Cancer
. 2021 Mar;
68(6):e28944.
PMID: 33773013
Background: Children treated for acute lymphoblastic leukemia (ALL) are at high risk of invasive pneumococcal disease (IPD). We assessed immunity to S. pneumoniae among children after ALL treatment, and the...
7.
Burns M, Place A, Stevenson K, Gutierrez A, Forrest S, Pikman Y, et al.
Pediatr Blood Cancer
. 2021 Jan;
68(3):e28885.
PMID: 33506554
No abstract available.
8.
Yao S, Zhu Q, Cole P, Stevenson K, Harris M, Schultz E, et al.
Blood Adv
. 2021 Jan;
5(2):451-458.
PMID: 33496737
Hispanic children have a higher incidence of acute lymphoblastic leukemia (ALL) and inferior treatment outcomes relative to non-Hispanic White children. We previously reported that Hispanic children with ALL had lower...
9.
Litalien C, Autmizguine J, Carli A, Giroux D, Lebel D, Leclerc J, et al.
Can J Hosp Pharm
. 2020 Oct;
73(4):247-256.
PMID: 33100356
Background: Many medications given to children have no commercially available, age-appropriate formulations. This leads to manipulation of dosage forms designed for adults (compounding), which can result in an increased risk...
10.
Burns M, Place A, Stevenson K, Gutierrez A, Forrest S, Pikman Y, et al.
Pediatr Blood Cancer
. 2020 Oct;
68(1):e28719.
PMID: 33026184
Background/objectives: While outcomes for pediatric T-cell acute lymphoblastic leukemia (T-ALL) are favorable, there are few widely accepted prognostic factors, limiting the ability to risk stratify therapy. Design/methods: Dana-Farber Cancer Institute...